VivoSeq
Immunology

Chronic Graft-Versus-Host Disease (cgvhd)

0

Pipeline Programs↗

4

Active Trials↗

4

Companies Involved↗

Chronic Graft-Versus-Host Disease (cGVHD) is an early-stage landscape with 0 programs across 4 companies. The most active players are Deciphera Pharmaceuticals, LLC, Grit Biotechnology, Sanofi.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

D

Deciphera Pharmaceuticals, LLC

0 programs

PreclinicalG

Grit Biotechnology

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalB

Beijing Tide Pharmaceutical Co., Ltd

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

4

clinical trials

Recruiting2 · 50%
Not yet recruiting1 · 25%
Active, not recruiting1 · 25%

Clinical Trials

Trial Activity

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
Recruiting·DDeciphera Pharmaceuticals, LLC·Phase 2·NCT06619561·48 enrolled
A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD)
Recruiting·GGrit Biotechnology·Phase 1·NCT07253259·36 enrolled
A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)
Not yet recruiting·Sanofi logoSanofi·Phase 4·NCT07135973·26 enrolled
TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD))
Active, not recruiting·BBeijing Tide Pharmaceutical Co., Ltd·Phase 1/2·NCT06169722·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)